m
Recent Posts
Connect with:
Tuesday / November 12.
HomeminewsStem Cells To Treat Dry AMD

Stem Cells To Treat Dry AMD

Retinal pigment epithelial (RPE) cells derived from human embryonic stem cells have been used to treat the fourth patient for dry age-related macular degeneration in one of three Phase I/II clinical trials being conducted by the American company Advanced Cell Technology (ACT).[/vc_column_text][/vc_column]

The surgery was performed on 1 August at Wills Eye Institute in Philadelphia.

The dry AMD trials are being carried out to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD or Stargardt’s macular dystrophy (SMD) at 12 months, the study’s primary endpoint. Each trial has enrolled 12 patients, with cohorts of three patients in an ascending dosage format.

“Doubling the cell dosage in both our U.S. trials is an important step forward in our clinical programs,” said Robert Lanza, M.D., ACT’s chief scientific officer. “We anticipate continued progress and safety findings in both our U.S. trials as well as our concurrent European trial.”

“Dry AMD is a form of macular degeneration with no approved drug treatment available to date,” said Dr. Carl Regillo who led the surgery. ACT’s hESC-derived RPE cells could address the unmet medical need of combating dry AMD and other macular degenerations such as Stargardt’s disease. We are looking forward to analysing the safety and efficacy data.”

DECLARATION

DISCLAIMER : THIS WEBSITE IS INTENDED FOR USE BY HEALTHCARE PROFESSIONALS ONLY.
By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.